Russian Scientific Center of Surgery named after Academician B.V. Petrovsky is conducting a clinical trial of gene-activated osteoplastic material for the treatment of patients with spine diseases. More than 200 patients have already been included in the study. A total of 300 patients will take part in the study. Gene-activated material for bone grafting was developed by Histograft, which is part of the Artgen Group. It has been used in clinical practice for bone grafting since 2020.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept